GKSL share price, P/E, ROE & financials

Gujarat Kidney And Super Speciality (GKSL) had a P/E of 61.4× on 6 Nov 2026, above the industry P/E of 47.7×, and the shares are 26% below their 52-week high. Sales fell 11% a year over 3 years while net profit grew 33%; its ROCE of 8.5% is the lowest among the 7 largest Medical Care Facilities peers. Debt is 0.11× equity. It is a small-cap company with a market cap of ₹1,229 Cr, ranked 21st of 40 Medical Care Facilities companies by market cap; the shares rose 49% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹160.43
Day high: ₹160.43
Day low: ₹154.27
Prev. close: ₹158.21
Volume: 2.4 L

Health check

2 good · 2 fair · 2 to check

ReturnsAhead
+49.1% over a year, better than 7 of 7 peers.
Price tagPricier
P/E 61.4 vs industry 47.7.
GrowthSteady
Sales −10.9%, profit +32.7% a year over 3 years.
ProfitabilityWeak
ROCE 8.5% vs peer median 11.9%.
Balance sheetFair
Debt 0.11× equity, interest covered 12.6×, Piotroski 4 of 9.
Red flagsNone found
No warning signs in the headline numbers.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Medical Care Facilities

39 listed peers. Screen the industry

Small cap

₹1,229 Cr, #21 of 40 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2026: sales ₹101 Cr · profit ₹16 Cr

Market cap: ₹1,229 Cr; Small cap
P/E: 61.4; Industry 47.7
Price to book: 4.87; Peers 8.06
Dividend yield: 0.00%
ROE: 11.1%; Peers 12.8%
ROCE: 8.5%; Peers 11.9%
Debt to equity: 0.11; Debt ₹29 Cr
EPS (TTM): ₹2.54; Face value ₹2
OPM (TTM): 29.2%; Net margin 15.7%
Sales growth: +124.7%; Latest quarter vs a year ago
Profit growth: +6.9%; Latest quarter vs a year ago
Price to sales: 12.17; EV/EBITDA 47.8

Strengths

Quarterly sales up 124.7% on a year ago.

No obvious red flags in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Gujarat Kidney And Super Speciality

Gujarat Kidney and Super Speciality Limited operates multi-specialty and super-specialty hospitals in India. It provides treatment for Oncology, Neurology, Gastroenterology, Urology, Nephrology, and Physiotherapy. It also offers Renal Surgery, Vascular Surgery, Gynecology and obstetrics, Robotic Surgery, Bariatric Surgery, Laparoscopic Surgery, Endocrine Surgery, Neurosurgery, and Joint Replacement services. Its facilities include intensive care unit,…

Headquarters: Vadodara
Employees: 194
Sector: Healthcare
ISIN: INE0V0W01025
Website: gujaratsuperspecialityhospital.com

Price range

52 weeks

₹98.36₹209.80

Today

₹154.27₹160.43

Avg volume (3M): 13.7 L
1-year return: plus 49.1%
From 52-week high: minus 25.7%

Peers · Medical Care Facilities

Compare with peers Screen the whole industry

Company
APOLLOHOSPApollo Hospitals Enterprise	8,446.00	plus 0.90%	1,21,441	54.0	11.45	19.2%	22.5%	15.4%	14.8%	33.3%	0.24%	plus 7.2%
MAXHEALTHMax Healthcare Institute	934.00	plus 0.21%	90,909	66.1	8.03	12.6%	12.8%	26.8%	22.4%	9.3%	0.21%	minus 18.1%
MANIPALHOSManipal Health Enterprises	646.70	minus 1.61%	85,065	133.6	9.05	9.8%	9.2%	17.8%	–	–	0.00%	minus 3.0%
ASTERDMAster DM Quality Care	713.15	minus 0.89%	62,092	90.7	8.06	9.4%	9.7%	17.4%	15.7%	−3.0%	0.42%	plus 4.5%
FORTISFortis Healthcare	766.90	minus 6.45%	57,898	55.7	5.52	11.9%	10.4%	22.2%	13.3%	20.9%	0.13%	minus 19.6%
NHNarayana Hrudayalaya	1,903.00	minus 0.65%	38,650	44.7	7.73	11.4%	19.1%	18.5%	20.5%	9.9%	0.24%	plus 4.7%
MEDANTAGlobal Health	1,387.60	minus 0.15%	37,264	60.4	8.63	15.0%	15.2%	22.1%	17.2%	19.5%	0.04%	plus 11.2%
GKSLGujarat Kidney And Super Speciality	155.92	minus 1.45%	1,229	61.4	4.87	8.5%	11.1%	29.2%	−10.9%	32.7%	0.00%	plus 49.1%
Median of 7 peers	–	−0.65%	62,092	60.4	8.06	11.9%	12.8%	18.5%	16.5%	14.7%	0.21%	4.5%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Mar 25	Jun 25	Dec 25	Mar 26	Jun 26
9.8	15.3	23.2	30.6	34.3
–	–	–	+212.6%	+124.7%
7.2	6.6	16.4	24.3	25.9
2.6	8.6	6.9	6.3	8.4
26.7%	56.5%	29.7%	20.6%	24.4%
0.1	0	0.1	0.7	0.7
0.2	0.2	0.6	0.8	0.7
0.9	1	1.3	1.5	1.4
1.6	7.5	5	4.7	7
16.9%	27.9%	26.3%	−3.0%	23.6%
1.3	4.8	2.9	5	5.2
–	–	–	+294.6%	+6.9%
0.16	0.61	0.52	0.81	0.66

Sep 25 not reported by the data source.

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: −10.9%
Profit CAGR 3Y: +32.7%
EPS CAGR 3Y: +43.5%
ROE: 11.1%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
85.8	103	36.8	60.6
–	+20.6%	minus 64.4%	+64.8%
68.2	88.4	23.7	55.1
17.6	15.1	13.1	5.5
20.5%	14.6%	35.6%	9.2%
0.3	1.2	0.1	0.8
2.1	2.3	0.6	1.8
6	0.3	3.3	4.7
–	–	3.5	21.4
9.8	13.6	12.8	21.2
35.4%	26.6%	25.6%	20.8%
6.6	9.7	9.4	15.5
–	+45.9%	minus 2.8%	+64.6%
0.84	1.23	1.19	2.49

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
0.2	0.2	11.4	15.8
21.8	22.1	14.6	237
23.2	27.3	8.3	29.1
18.7	15.8	21.1	16
63.9	65.4	55.3	298
38.3	37.5	23.9	96.8
–	–	–	59
1.5	2	1.6	2.4
2.2	4.4	2.8	56.1
21.9	21.5	27.1	83.4
63.9	65.4	55.3	298

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
0	1.2	13.6	−3.9
–	0.2	−18.1	−214
–	−0.5	6.2	228
0	1	1.6	10.7
–	–	−18.2	−94.4
0	1.2	−4.6	−98.3

Shareholding pattern

Source: NSE filings

71.5%

promoters

Promoters71.45%
Public28.55%
As of 30 Sep 2026

Quarter	Promoters	Public	Promoter change
30 Sep 2026	71.45%	28.55%	0.00
30 Jun 2026	71.45%	28.55%	0.00
31 Mar 2026	71.45%	28.55%	0.00
31 Dec 2025	71.45%	28.55%	0.00
29 Dec 2025	71.45%	28.55%	–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you